TREACE MEDICAL CONCEPTS, INC. Cash and Equivalents

Quick Answer

TREACE MEDICAL CONCEPTS, INC. reported Cash and Equivalents of $10.71 million for fiscal year 2025.

TREACE MEDICAL CONCEPTS, INC. Cash and Equivalents — Annual History

Fiscal Year Cash and Equivalents YoY Change
2025 $10.71M -5.7%
2024 $11.35M -12.6%
2023 $12.98M -33.3%
2022 $19.47M -81.6%
2021 $105.83M +485.4%
2020 $18.08M +48.9%
2019 $12.14M +845.4%
2018 $1.28M

Quarterly Cash and Equivalents

Quarter Ending Cash and Equivalents YoY QoQ
September 30, 2025 $7.69M -36.5% -4.5%
June 30, 2025 $8.05M -55.7% -39.8%
March 31, 2025 $13.37M +43.3% +17.8%
December 31, 2024 $11.35M -12.6% -6.3%
September 30, 2024 $12.11M +66.4% -33.4%
June 30, 2024 $18.18M +51.1% +94.8%
March 31, 2024 $9.33M -68.5% -28.1%
December 31, 2023 $12.98M -33.3% +78.4%
  • TREACE MEDICAL CONCEPTS, INC. showed a decrease of -5.7% in Cash and Equivalents compared to the prior fiscal year.
  • Over the 2018–2025 period, TREACE MEDICAL CONCEPTS, INC.’s cash and equivalents has grown by 734.0% (from $1.28 million to $10.71 million).
  • The most recent figure is from TREACE MEDICAL CONCEPTS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 27, 2026.
  • All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.

Last verified:

Leave a Comment